This rebranding strategy reflects both the evolution of the company as well as its vision towards the longevity, healthcare, wellness, and life sciences sectors for the future.
Jamie Gibson, Chief Executive Officer of the Company, said, "We are excited to introduce our new company identity as it reflects the Group's business strategies, focus and market positioning, and its determination to make a statement in the future of the longevity business, as well as enhancing its corporate image and competitiveness, especially after the acquisition of Deep Longevity, a company developing artificial intelligence to track human aging and extend productive longevity. The acquisition of Deep Longevity injected state-of-the-art aging clock technologies and exceptional brand value into the Group. With a burgeoning number of elderlies and increasing focus on geroprotection, extending human life and improving performance are of utmost important, which will create huge business opportunity for the longevity industry."
Jamie added, "In addition, Fortacin, our core treatment for PE is expected to benefit with the introduction of mainlandChina's Three Child Policy in May 2021. It is estimated that Fortacin will be launched in mainland China in 2023 and has the potential to help an initial target market of approximately 9 million patients in mainland China in its first year of launch."
About Endurance RP Limited (Stock code: 0575.HK)
Endurance RP Limited is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare, wellness and life sciences sectors. The Group has a strong track record of investments and has returned approximately US$298 million to shareholders in the 23 years of financial reporting since its initial public offering in May 1997.
www.endurancerp.com
SOURCE Regent Pacific Group Limited
© 2021 PR Newswire
